GSK PLC Strengthens Healthcare Position with $2 Billion Efimosfermin Acquisition and Meningitis B Vaccine Campaign
GSK PLC has made significant strategic moves, including the acquisition of efimosfermin for up to $2 billion, to bolster its position in the healthcare sector and address critical health issues.
3 minutes to read